|
1
|
National Kidney Foundation: K/DOQI
clinical practice guidelines for chronic kidney disease:
evaluation, classification, and stratification. Am J Kidney Dis.
39(2 Suppl 1): S1–S266. 2002.PubMed/NCBI
|
|
2
|
Japanese Society of Nephrology:
Evidence-based practice guideline for the treatment of CKD. Clin
Exp Nephrol. 13:537–566. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Harris D, Thomas M, Johnson D, Nicholls K
and Gillin A; Caring for Australasians with Renal Impairment
(CARI): The CARI guidelines. Prevention of progression of kidney
disease. Nephrology (Carlton). 11(Suppl 1): S2–S197. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lamb EJ: United Kingdom guidelines for
chronic kidney disease. Scand J Clin Lab Invest Suppl. 241:16–22.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bakris GL, Toto RD, McCullough PA, Rocha
R, Purkayastha D and Davis P: Effects of different ACE inhibitor
combinations on albuminuria: results of the GUARD study. Kidney
Int. 73:1303–1309. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Matsui Y, Eguchi K, O’Rourke MF, Ishikawa
J, Shimada K and Kario K: Association between aldosterone induced
by antihypertensive medication and arterial stiffness reduction:
the J-CORE study. Atherosclerosis. 215:184–188. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Matsuo S, Imai E, Horio M, et al: Revised
equations for estimated GFR from serum creatinine in Japan. Am J
Kidney Dis. 53:982–992. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Verhave JC, Gansevoort RT, Hillege HL,
Bakker SJ, De Zeeuw D and de Jong PE; PREVEND Study Group: An
elevated urinary albumin excretion predicts de novo development of
renal function impairment in the general population. Kidney Int
Suppl. S18–S21. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hillege HL, Fidler V, Diercks GF, et al:
Urinary albumin excretion predicts cardiovascular and
noncardiovascular mortality in general population. Circulation.
106:1777–1782. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Arnlov J, Evans JC, Meigs JB, et al:
Low-grade albuminuria and incidence of cardiovascular disease
events in nonhypertensive and nondiabetic individuals: the
Framingham Heart Study. Circulation. 112:969–975. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gerstein HC: Diabetes and the HOPE study:
implications for macrovascular and microvascular disease. Int J
Clin Pract Suppl. 8–12. 2001.PubMed/NCBI
|
|
12
|
Gaede P, Tarnow L, Vedel P, Parving HH and
Pedersen O: Remission to normoalbuminuria during multifactorial
treatment preserves kidney function in patients with type 2
diabetes and microalbuminuria. Nephrol Dial Transplant.
19:2784–2788. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mann JF, Gerstein HC, Yi QL, et al:
Progression of renal insufficiency in type 2 diabetes with and
without microalbuminuria: results of the Heart Outcomes and
Prevention Evaluation (HOPE) randomized study. Am J Kidney Dis.
42:936–942. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Asselbergs FW, Diercks GF, Hillege HL, et
al: Effects of fosinopril and pravastatin on cardiovascular events
in subjects with microalbuminuria. Circulation. 110:2809–2816.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
de Zeeuw D, Remuzzi G, Parving HH, et al:
Albuminuria, a therapeutic target for cardiovascular protection in
type 2 diabetic patients with nephropathy. Circulation.
110:921–927. 2004.PubMed/NCBI
|
|
16
|
Ibsen H, Olsen MH, Wachtell K, et al:
Reduction in albuminuria translates to reduction in cardiovascular
events in hypertensive patients: losartan intervention for endpoint
reduction in hyper-tension study. Hypertension. 45:198–202. 2005.
View Article : Google Scholar
|
|
17
|
Halimi JM, Buchler M, Al-Najjar A, et al:
Urinary albumin excretion and the risk of graft loss and death in
proteinuric and non-proteinuric renal transplant recipients. Am J
Transplant. 7:618–625. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Heinze G, Mitterbauer C, Regele H, et al:
Angiotensin-converting enzyme inhibitor or angiotensin II type 1
receptor antagonist therapy is associated with prolonged patient
and graft survival after renal transplantation. J Am Soc Nephrol.
17:889–899. 2006. View Article : Google Scholar
|
|
19
|
Iñigo P, Campistol JM, Saracho R, et al:
Renoprotective effects of losartan in renal transplant recipients.
Results of a retrospective study. Nephron Clin Pract. 95:c84–c90.
2003.PubMed/NCBI
|
|
20
|
Uchida J, Machida Y, Iwai T, et al:
Low-grade albuminuria reduction with angiotensin II type 1 receptor
blocker in renal transplant recipients. J Nephrol. 24:515–521.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Palmer BF: Metabolic complications
associated with use of diuretics. Semin Nephrol. 31:542–552. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kita T, Yokota N, Ichiki Y, et al:
One-year effectiveness and safety of open-label
losartan/hydrochlorothiazide combination therapy in Japanese
patients with hypertension uncontrolled with ARBs or ACE
inhibitors. Hypertens Res. 33:320–325. 2010.PubMed/NCBI
|
